Funding Opportunities

submenu

News and notices


NOT-CA-17-006

Notice Award Administration Information for NCI Outstanding Investigator Award (R35)
This notice provides clarification on future NCI grant support to NCI’s Outstanding Investigator Award (OIA) (R35) recipients.  As indicated in the Funding Opportunity Announcement (FOA), future applications submitted after the OIA is awarded will not be folded into the R35 award; however, the 6 calendar month level of effort on the OIA must be maintained for the entire 7-year project period. This Notice clarifies that NCI will only consider funding two additional research project grants to the Outstanding Investigator while the OIA is active.  This limit includes single PD/PI, multiple PD/PI and multi-project grants. In addition, any grant that was relinquished at the time the OIA was awarded should not be submitted for renewal and will not be considered for funding by NCI.


NOT-OD-17-003

Ruth L. Kirschstein National Research Service Awards (NRSA) Postdoctoral Stipends, Training Related Expenses, Institutional Allowance, and Tuition/Fees Effective for Fiscal Year 2017
All FY 2017 awards previously issued using FY 2016 stipend levels will be revised to adjust stipends to the FY 2017 level. Appointments to institutional training grants that have already been awarded in FY 2017 must be amended to reflect the FY 2017 stipend levels once the training grant award has been adjusted by the NIH. Amended appointments must be submitted through xTrain in the eRA Commons.


NOT-OD-17-023

Revised SF424 (R&R) Application Guides and Supplemental Instructions Available

This Notice informs the biomedical and health services research communities that we have updated our application guide and supplemental instructions.
Based on applicant feedback, we have made minor changes to the layout and style of our instructions, located on the How to Apply – Application Guide webpage. We hope that these changes will make it easier for our applicants to find the information they need. We have also incorporated several clarifications to our current Forms-D instructions.


NOT-OD-17-002

NIH Implementation of Final Research Performance Progress Reports (Final RPPR)

The National Institutes of Health intends to replace the Final Progress Report (FPR) with the Final Research Performance Progress Report (Final RPPR) through a new eRA Commons module effective January 2017.

Adjustment to Stipend Levels for Postdoctoral Trainees and Fellows on Ruth L. Kirschstein National Research Service Awards (NRSA)

The purpose of this Notice is to announce the process whereby recipients of Kirschstein-NRSA institutional training grant and individual fellowship awards supporting currently active postdoctoral trainees or fellows with 0, 1, or 2 years of experience as of December 1, 2016, will received increased stipends. The Notice also provides instructions for requesting one-time supplemental funding to cover the stipend increase.


 NOT-OD-17-005

Electronic Submission Method to Request Application Exceeding $500,000 Direct Costs
NIH has a longstanding policy that states any applicant requesting $500,000 or more in direct costs (excluding consortium F&A costs) in any one budget period within a competitive segment is required to contact the NIH Institute or Center (IC) Program Official (PO), in writing or by telephone, as early as possible during development of the application but no later than 6 weeks before submission for prior approval. After initial communication with the NIH, a PO may open up a request form for the Principal Investigator (PI) in eRA Commons, under a new Prior Approval Module. The PI will complete the form and submit it back to the initiating PO for review.


 

 

External funding opportunities

PAR-17-049

NCI Research Specialist (Laboratory-based Scientist) Award (R50)

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Funding:

Application budgets may request the following two expenses in direct costs per year:

1) salary support for the Research Specialist commensurate with their current level of funded effort (at least 6-person months) on NCI-funded research grants; and,

2) travel costs to attend research meetings/conferences not to exceed $2,500 per year

The maximum award period is 5 years.

Key Dates:

Full application due February 2, 2017


PAR-16-457

National Cancer Institute Program Project Applications (P01)

With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Funding:

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Key Dates:

Full application due January 25, 2017


Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)

NIH/NCI

This Funding Opportunity Announcement (FOA) invites cooperative agreement (U54) applications for the implementation of Comprehensive Partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI-designated Cancer Centers (CC). The purpose of this limited competition funding opportunity announcement (FOA) is to continue fostering and supporting intensive collaborations among investigators at ISUPS and CCs in order to develop stronger national cancer programs aimed at understanding the reasons behind the significant cancer disparities and related impacts on these populations. This FOA is intended for: (1) supporting active Comprehensive Partnerships under the U54 mechanism or inactive Comprehensive Partnerships but formerly supported by the U54 mechanism; and (2) elevating the promising U56 partnerships and other similar partnerships to the comprehensive status.

Funding:

Applications are limited to $2.5 million Direct costs per year for dyads and $3.0 million Direct cost per year for triads

The maximum period is 5 years.

Key Dates:

Full application due January 28, 2017


Spring 2017 Grant Opportunities

St. Baldrick’s Foundation
*Internal review coordination through Academic Health Center.
UMN is allowed to submit one application per grant opportunity, and two for the Research Grants. Grants include:
- St. Baldrick's Fellows
- St. Baldrick's Scholars
- St. Baldrick's International Scholars
- Research Grants
- Supportive Care Research Grants
- St. Baldrick's Summer Fellows
An individual PI can only apply to one of the grant opportunities. This includes the Consortium Research Grants though we are not limited to one LOI in that category. Please see RFP for further information about each funding type.

Funding:

See individual grant details for more info. Grants range from $5,000 to $330,000

Key Dates:

*If you are interested in applying, please send a draft of the LOI as requested by St. Baldrick's to Jessica Van Gilder, (vangi007@umn.edu), no later than 4pm on January 23rd.
Letters of Intent due January 31, 2017
Full Applications due March 31, 2017


PAR-17-049

NCI Research Specialist (Laboratory-based Scientist) Award (R50)

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Funding:

Application budgets may request the following two expenses in direct costs per year:

1) salary support for the Research Specialist commensurate with their current level of funded effort (at least 6-person months) on NCI-funded research grants; and,

2) travel costs to attend research meetings/conferences not to exceed $2,500 per year

The maximum award period is 5 years.

Key Dates:

Full application due February 2, 2017


PAR-17-050

NCI Research Specialist (Core-based Scientist) Award (R50)

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research.  This FOA is specifically for core/shared resource/central scientific support scientists.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators.  These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise.  The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Funding:

Application budgets may request the following two expenses in direct costs per year:

1) salary support for the Research Specialist commensurate with their current level of funded effort (at least 6-person months) on NCI-funded research grants; and,

2) travel costs to attend research meetings/conferences not to exceed $2,500 per year

The maximum award period is 5 years.

Key Dates:

Full application due February 2, 2017


PA-16-012

Examination of Survivorship Care Planning Efficacy and Impact (R01)
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes.

Funding: 

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Key Dates:

Full application due February 5, 2017


PA-16-160

NIH Research Project Grant (Parent R01)
The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding:

Application budgets are not limited but need to reflect the actual needs of the proposed project. The max project period is 5 years.

Key Dates:

Full application due February 5, 2017


RFA-CA-16-017

Coordinating Center for Population-based Research to Optimize the Screening Process (PROSPR) (U24)
The overall goal for the PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple healthcare environments in the United States. The intent of this FOA is to fund a single Coordinating Center that will support a network of three PROSPR Research Centers (PRCs; one each focused on cervical, colorectal, and lung cancer). Specifically, the Coordinating Center will facilitate the development of common measures across cancer types for (1) system-level factors that may impact the cancer screening process, and (2) quality of screening. It will also coordinate PROSPR network research projects that include more than one cancer type. Finally, the Coordinating Center will be responsible for developing and implementing a process for PROSPR data access and sharing with qualified investigators outside of the PROSPR network.

Funding:

$1,000,000 in direct costs per year.  A project period of 5 years must be proposed.

Key Dates:

Full application due February 9, 2017


PAR-17-069

NCI Transition Career Development Award to Promote Diversity (K22)
The purpose of the NCI Career Transition Award to Promote Diversity program is to assist a postdoctoral fellow's transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years for recipients to develop and receive support for their initial cancer research program. 

Funding:

NCI will contribute up to $100,000 per year toward the salary of the career award recipient (total salary may not exceed the salary cap).  NCI will contribute $ 50,000 per year toward the research development costs of the award recipient.

Key Dates:

Full application due February 12, 2017.


Precision Medicine Target Grant

Pancreatic Cancer Action Network

Funding available for projects that can be incorporated directly into the Pancreatic Cancer Action Network’s Precision Promise initiative at the end of the funding period. Applications from academic institutions or for-profit biotechnology or pharmaceutical firms are accepted.

Funding:

Up to $1,000,000\two years

Key Dates:

Application deadline: February 15, 2017, Noon EST


PAR-16-176

NCI Clinical and Translational Exploratory/Developmental Studies (R21)

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

Funding:

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Key Dates:

Full application due February 21, 2017


Early Detection Targeted Grant

Pancreatic Cancer Action Network
Supports studies utilizing a cohort of new onset diabetics with high risk of sporadic pancreatic cancer; projects will focus on blood biomarkers or imaging strategies

Funding:

Up to $1,000,000 in milestone-driven units of $250,000, up to four years

Key Dates:

Deadline: February 22, 2017, Noon EST


RFA-CA-17-010

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Funding:

$400,000 Direct Costs over a 3-year period, with no more than $200,000 allowed in any single year.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-011

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.

Funding:

$300,000 Direct Costs per year for a maximum of 3 years.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-012

Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Funding:

Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-013

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Funding:

Direct costs are limited to $300,000 per year for a maximum of 3 years.

Key Dates:

Full application due February 28, 2017


RFA-CA-17-004

PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)
The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of four PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-17-003) in a collaborative network. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include: development of new PDX models and methods for preclinical testing of single agents and drug combinations; and using the newly established models as well as other existing well-characterized PDX models for studies of drug responses. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI’s Experimental Therapeutic Clinical Trials Network (ETCTN).

Funding:

Application budgets must reflect the actual needs of the proposed project but must not exceed $650,000 per year in direct costs, for a period of 5 years.

Key Dates:

Full application due March 3, 2017


RFA-CA-17-003

PDX Development and Trial Centers (PDTCs)(U54)
This funding opportunity announcement (FOA) solicits applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine.
The main goals for PDTCs include:
Development of new PDX models and methods for preclinical testing of single agents and drug combinations; and
Conducting studies of response of PDX models to novel therapeutic strategies using the newly established models as well as other existing well-characterized PDX models.
It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI’s Experimental Therapeutic Clinical Trials Network (ETCTN).

Funding:

Application budgets must not exceed $800,000 per year in direct costs for period of 5 years.

Key Dates:

Full application due March 3, 2017


RFA-CA-17-009

Mechanisms of Cancer Drug Resistance and Sensitivity (U54)
The goal of this FOA is to create a network of Drug Resistance and Sensitivity Centers (DRSCs) to develop innovative strategies to study mechanisms of tumor resistance or sensitivity to anticancer therapy.  It is hoped that such studies will permit future efforts to identify and exploit these phenomena in clinical settings. Each funded DRSC will become a member of the Drug Resistance and Sensitivity Network.  Each DRSC may include multiple members and capabilities at the same or different institution that are necessary to fulfill the need for highly specialized multidisciplinary expertise.  There may be multiple linked projects within each DSRC that will be under the overall authority of a Program Director/Principal Investigator (PD/PI).  Applications involving several investigators from single or multiple institutions working together on a promising area of cancer resistance or sensitivity to drug therapy are encouraged. The outputs from the DRSCs are expected to inform the development of novel strategies for precision medicine clinical trials (beyond the scope of this FOA) that can overcome drug resistance and sensitivity to anti-cancer agents.

Funding:

$750,000 per year in direct costs, for a max of 5 years.

Key Dates:

Full application due March 3, 2017


Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation

This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers. Applicants are not required to be pediatricians or members of pediatric departments; however, the proposed research must have direct relevance to one or more pediatric cancers. The goal of this Fellowship Award is to recruit the top young minds to research childhood cancers. It leverages the success of the internationally-renowned Damon Runyon Fellowship Award, which has an unparalleled track record for identifying future breakthrough scientists.

Funding:

This four year award is $52,000, $54,000, $57,000 and $60,000 for years one, two, three, and four, respectively. In addition, an annual $2,000 expense allowance is awarded to the laboratory in which the Fellow is working and can be used by the Fellow for his/her educational and scientific expenses. The Foundation also provides a Dependent Child Allowance of $1,000 per child per year. The award may not be used for institutional overhead or indirect costs.

Key Dates:

Full application due March 15, 2017


BD Biosciences Cancer Research Grant

A total of $100,000 worth of research reagents are awarded annually to 10 scientists. Through the grant program, BD Biosciences supports scientists pursuing innovative ideas in cancer research, helping to define the next generation of scientific breakthroughs.

Funding:

$100,000 in research reagents

Key dates:

Full Application due April 1, 2017


Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)

(NOT-OD-15-044)
(PAR-15-075)
National Cancer Institute

Funding:

Standard R01 limits apply

Application Receipt Date(s):

Standard dates apply, by 5:00 PM local time of applicant organization.


NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

(PAR-15-064)
National Cancer Institute

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses

Application Receipt Date(s):

Multiple dates, see announcement.


NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)

(PAR-15-062)
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

$100,000/yr towards salary; $30,000/yr for other expenses


National Cancer Institute Program Project Applications (P01)

(PAR-15-023)
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement

Funding:

Varies


Advancing Interventions to Improve Medication Adherence

PA-14-334 – R01 and PA-14-335 – R21
National Cancer Institute

Application Receipt Date(s):

Multiple dates, see announcement.

Funding:

Standard R01 & R21 limit


Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)

(PAR-14-242)
National Cancer Institute

Application Receipt Date(s):  

See announcement for dates.

Funding:

Standard R01 limits apply 


Interventions for Health Promotion and Disease Prevention in Native American Populations (R01)

(PAR-14-260)
National Cancer Institute

Application Receipt Date(s):

See announcement for dates.

Funding:

Standard R01 limits apply.


Genomic Resource Grants for Community Resource Projects (U41)

(PAR-14-191)
National Cancer Institute

Funding:

5 years of funding.  Application budgets are not limited, but should reflect the needs of the proposed project.

Application Receipt Date(s):

January 25, 2017


Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)

(PA-14-114)
National Cancer Institute

Funding:

Standard R01 limits apply.

Application Receipt Date(s):

Multiple dates, see announcement


Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

(PAR-14-013)
National Cancer Institute

Funding:

Standard R21 limits apply

Deadline:

See announcement for dates.


Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)

(PAR-14-116)
National Cancer Institute

Funding:

$500,000/yr for 5 years

Application Receipt Date(s):

Multiple dates, see announcement 


Modeling Social Behavior (R01)

(PAR-13-374)
National Cancer Institute

Funding:

Standard R01 limits apply

Deadline:

Multiple dates, see announcement


Research to Characterize and Reduce Stigma to Improve Health

R01 (PA-13-248), R03 (PA-13-247) and R21 (PA-13-246)

National Cancer Institute

Funding:

Standard limits apply.

Application Receipt Date(s):

Multiple dates, see announcement.  Standard cycle dates.


Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness

R01 (PA-13-165), R15 (PA-13-166) and R21 (PA-13-167)

National Cancer Institute

Funding:

Standard limits apply. See announcements for additional information

Application Receipt Date(s):

Multiple dates, see announcement.


Bioengineering Research Grants (BRG) (R01)

(PAR-13-137)
National Cancer Institute

Funding:

Standard R01 limits apply.

Application Deadline: 

Multiple receipt dates, see announcement.


Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

(PAR-13-169)
National Cancer Institute

Funding:

Standard R01 limits apply

Application Receipt Date(s):

Multiple dates, see announcement.

MCC and UMN funding opportunities

Masonic Cancer Center Internal Funding Opportunities

Other University of Minnesota Funding Opportunities

  • University of Minnesota - Physical Sciences in Oncology Center (PSOC) RFP for Pilot Project
    Program Summary: The UMN Physical Sciences in Oncology Center seeks proposals for highly innovative and potentially transformative ideas to advance fundamental research or the translation of discoveries to significant clinical applications in understanding and controlling cell migration in cancer. Proposals should reflect new ideas of the proposing investigators to pursue a potentially high impact research project. The awards are part of the University of Minnesota Physical Sciences in Oncology Center (PS-OC) funded through the National Cancer Institute’s Office for Physical Sciences in Oncology, which seeks to develop a cell migration simulator to aid in predicting patient outcomes and identifying new therapeutic targeting strategies.Project Period: The project period is from Feb. 17, 2017 to July 31, 2017, with an opportunity to apply for additional funding beyond this initial period. We expect to make 2-4 awards with award sizes up to $50,000
    Deadline: Applications should be submitted in a single pdf to psoc@umn.edu by February 6, 2017, 4 p.m.

Funding resources

Federal agencies funding cancer-related research

Search funding opportunities; sign up to receive the NIH Guide weekly via e-mail.

Search for funding sources by keyword; sign up for e-mail notification of funding opportunities. (Note: NIH listings are under DHHS, the Department of Health and Human Services.)

Non-federal agencies funding cancer-related research

Research funding directories

CFDA is a database of all federal programs available to state and local governments; federally recognized Indian tribal governments; territories (and possessions) of the United States; domestic public, quasi-public, and private profit and nonprofit organizations and institutions; specialized groups; and individuals.

This funding opportunity search engine provides the world's most comprehensive funding resource, with more than 24,000 records representing nearly 400,000 opportunities ranging from local non-profit funding to federally funded grants.

This is a sortable database of current funding opportunities pulled from various databases. It boasts a user-friendly interface and a comprehensive listing. While the listing is not as comprehensive as other databases in this list, opportunities may be easier to find in this abbreviated format.

(requires x.500 login)

The premier grantseeking database on the Web, developed by the Foundation Center, a national nonprofit service organization founded over 50 years ago to open up U.S. foundations to public view.

A fee-based service, to which the University of Minnesota is a current subscriber. It currently contains over 9,000 active federal and private funding opportunities in the sciences, social sciences, arts, and humanities. In addition to funding opportunities for faculty, the GrantForward Database also contains fellowships and scholarships for grad students and undergrads. Users can search  by sponsor, deadline date, keyword, and other criteria. Most GrantForward records contain live links to sponsor Web sites, electronic forms, or Electronic Research Administration (eRA) portals. The database is updated daily.

InfoEd's SPIN is the most widely used funding opportunity database in the world. By aggregating sponsor information in one system, SPIN dramatically cuts search times and substantially increases the likelihood of positive results. Program information is presented in a standard format that allows investigators to readily compare opportunities. This search engine is great for post-doctoral associates looking for funding opportunities.